iwCLL 2023 | Associated toxicities of novel therapies for CLL
Florian Simon
• 8 Oct 2023
Florian Simon, MD, University Hospital Cologne, Cologne, Germany, outlines some considerations when selecting an appropriate therapy for patients with chronic lymphocytic leukemia (CLL). This remains an important issue due to the distinct toxicities associated with available agents and how these may negatively impact patients if clinicians fail to address comorbidities and fitness prior to initiating treatment. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
